Is StriVectin Better Than Botox? Not Without NDA Approval, FDA Says
This article was originally published in The Rose Sheet
Executive Summary
Klein-Becker's signature statement for StriVectin-SD anti-aging cream - "Better than Botox?" - constitutes a structure/function claim that would require the product to be regulated as a drug, the agency states in a 1warning letter recently posted on its Web site
You may also be interested in...
Cosmeceutical Pioneer Strivectin’s ‘Anti-Aging Solutions’ Draw Drug Claim Warning
FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.
Cosmeceutical Pioneer Strivectin’s ‘Anti-Aging Solutions’ Draw Drug Claim Warning
FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits.
Will Cosmeceutical Pioneer Turn Its Wagons Around? FDA Warns Strivectin
FDA cites Strivectin’s Potent Wrinkle Reducing Treatment and TL Advanced Tightening Neck Cream as unapproved drugs based on claims touting elastin-stimulating effects, skin-firming action and other structure/function benefits. Widely credited as a pioneer that helped create the cosmeceutical category, Strivectin has been warning-free since 2005 when FDA came down on its “Better than Botox?” positioning.